| Name | Title | Contact Details |
|---|
ERMI is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iScience Interventional is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedManage Systems is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orthofix Medical Inc. began in a small farmhouse in Verona Italy in 1980 when orthopedic researcher Giovanni De Bastiani recognized the bone`s natural repair capability, a concept he called “dynamization.” With that in mind, he created the first external fixation device. Today, Orthofix has grown to more than 1,200 employees with locations in the U.S., Italy, Germany, France, the U.K., Brazil, and Australia. Our products help patients in more than 70 countries around the world. The Company`s mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, the company has two strategic business units: Spine and Orthopedics. Orthofix products are widely distributed via the company`s sales representatives and distributors. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as MTF Biologics, the Orthopedic Research and Education Foundation, and the Texas Scottish Rite Hospital for Children. Orthofix makes a difference in the lives of others by providing our surgeon customers with innovative medical devices to meet the needs of their patients. Every day we are optimizing our operations, improving efficiencies, and examining our systems to provide the best support possible to our representatives, surgeons and patients.
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.